Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,407 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Volunteers Clear all
Recruiting Phase 1 Interventional

A Study of PATAS Using Single Ascending Doses in Healthy Volunteers and Multiple Ascending Doses in Diabetic Subjects

NCT07223333
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
PATAS Trifluoroacetate, Placebo
Drug
Lead sponsor
AdipoPharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Chandler, Arizona • Miami, Florida • Port Orange, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 21, 2026, 10:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Heel Offloading Devices for Reducing Heel Contact Pressures in Healthy Volunteers

NCT02811965
View directory record Official record
Conditions
Heel Pressure Ulceration Prevention Strategies
Interventions
Pillow Condition 1, Pillow Condition 2, Heel Foam Pillow, Offloading Device A, Offloading Device B, Offloading Device C
Other · Device
Lead sponsor
DeRoyal Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Oct 21, 2026, 10:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

AB103 Peptide Antagonist in Healthy Volunteers

NCT01166984
View directory record Official record
Conditions
Healthy Volunteer Safety Study
Interventions
AB103, Placebo
Drug
Lead sponsor
Atox Bio Ltd
Industry
Eligibility
18 Years to 40 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 21, 2026, 10:32 AM EDT
Completed No phase listed Observational

Serotonin Function During Depression

NCT00033787
View directory record Official record
Conditions
Depression, Involutional, Healthy
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 60 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 10:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers

NCT01674218
View directory record Official record
Conditions
Tuberculosis
Interventions
Moxifloxacin, PA-824, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2014 · Synced Oct 21, 2026, 10:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects

NCT01860703
View directory record Official record
Conditions
Prolonged QTc Interval
Interventions
Deferiprone, deferiprone matching placebo tablets, moxifloxacin, placebo
Drug
Lead sponsor
ApoPharma
Industry
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 12, 2014 · Synced Oct 21, 2026, 10:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers

NCT02846142
View directory record Official record
Conditions
Healthy Volunteer
Interventions
PTI-428, Placebo, ethinyl estradiol and levonorgestrel
Drug · Other
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 21, 2026, 10:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Dose Safety Study of APD791 in Healthy Volunteers

NCT00529646
View directory record Official record
Conditions
Healthy
Interventions
APD791
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
19 Years to 45 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 30, 2008 · Synced Oct 21, 2026, 10:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Graded Insulin Suppression Test P&F

NCT06592261
View directory record Official record
Conditions
Insulin Resistance, Hyperinsulinemia, Obesity, Healthy
Interventions
Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia), Insulin regular, 32 mU/m2/min (hyperinsulinemia), Octreotide Acetate, 6-45 ng/kg/min, Dextrose 20 % in Water, Glucagon, 0-0.5 ng/kg/min
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 10:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of KP-001 on the QT/QTc Intervals in Healthy Adults

NCT06649942
View directory record Official record
Conditions
Healthy Volunteers - Male and Female
Interventions
KP-001, Moxifloxacin 400 mg, Placebo
Drug
Lead sponsor
Kaken Pharmaceutical
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 21, 2026, 10:32 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Microneurography and Spinal Cord Stimulation in Chronic Visceral Pain

NCT00678717
View directory record Official record
Conditions
Chronic Pain
Interventions
Autonomic Evaluation
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 16, 2018 · Synced Oct 21, 2026, 10:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Do Furanocoumarins Mediate the Fexofenadine-grapefruit Juice Interaction?

NCT01526213
View directory record Official record
Conditions
Food-drug Interaction
Interventions
Fexofenadine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 21, 2026, 10:32 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effect of TA-65MD on Healthy Volunteers

NCT02766790
View directory record Official record
Conditions
Healthy
Interventions
TA-65MD, Placebo
Dietary Supplement · Other
Lead sponsor
Telomerase Activation Sciences, Inc
Industry
Eligibility
45 Years to 75 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Springfeild, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 21, 2026, 10:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects

NCT05368935
View directory record Official record
Conditions
Renal Impairment, Renal Disease, Kidney Disease
Interventions
Nitazoxanide
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 80 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Oct 21, 2026, 10:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety Study of AZT-04 for Cosmetic Use

NCT03820076
View directory record Official record
Conditions
Study of Three Doses of AZT-04 for Skin Appearance
Interventions
AZT-04
Other
Lead sponsor
Azitra Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Irving, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 21, 2026, 10:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders

NCT03266068
View directory record Official record
Conditions
Campylobacter Infections, Irritable Bowel Syndrome
Interventions
DNA Analysis of Blood Sample, Flexible sigmoidoscopy with colonic biopsies, Small bowel and colonic gastrointestinal permeability, Stool sample analysis
Genetic · Procedure · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 21, 2026, 10:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetic Studies to Identify Stroke Subtypes and Outcome

NCT00357513
View directory record Official record
Conditions
Cerebrovascular Disease, Stroke
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
21 Years and older
Enrollment
840 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
3
States / cities
Bethesda, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 10:32 AM EDT
Completed Not applicable Interventional Results available

Effect of Formoterol on the Counterregulatory Hormonal Response to Hypoglycemia in Type 1 Diabetes.

NCT01194479
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Formoterol, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Oct 21, 2026, 10:32 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease

NCT07235059
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
OJR520, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 21, 2026, 10:32 AM EDT
Recruiting Not applicable Interventional

Health Care Transition Readiness Short-Form Video Intervention

NCT06842576
View directory record Official record
Conditions
Health Care Transition Readiness, Health Literacy, Self Efficacy, Emotional Wellbeing, Appointment Attendance
Interventions
Health Education Videos, GotTransition.org Website
Behavioral
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
12 Years to 17 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 21, 2026, 10:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Effect on Heart Rhythm of 3 Days of GSK189075, Placebo, or Moxifloxacin in Healthy Adults

NCT00532610
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Interventions
GSK189075
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 21, 2026, 10:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers

NCT02955459
View directory record Official record
Conditions
Bacterial Infections
Interventions
VNRX-5133, Placebo
Drug
Lead sponsor
Venatorx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 21, 2026, 10:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First In Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429 Administered Intravenously To Healthy Adult Volunteers

NCT01011296
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PF-04427429
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 21, 2026, 10:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase IC Study of Safety and PK of SQ109 300mg Daily

NCT01358162
View directory record Official record
Conditions
Tuberculosis
Interventions
Placebo, SQ109
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 21, 2026, 10:32 AM EDT